Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

60.21
+4.267.61%
Volume:896.92K
Turnover:54.52M
Market Cap:2.27B
PE:-11.10
High:62.63
Open:55.62
Low:55.51
Close:55.95
52wk High:99.50
52wk Low:30.82
Shares:37.75M
Float Shares:32.58M
Volume Ratio:7.31
T/O Rate:2.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4247
EPS(LYR):-3.9613
ROE:-34.78%
ROA:-22.61%
PB:3.96
PE(LYR):-15.20

Loading ...

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones
·
37 mins ago

Disc Medicine price target lowered to $75 from $120 at Morgan Stanley

TIPRANKS
·
1 hour ago

Disc Medicine Exec Says That IF Late-Stage Trial Succeeds, Co Will Seek Approval Through the Traditional Pathway Rather Than the Accelerated Route – Conf Call

THOMSON REUTERS
·
1 hour ago

Disc Medicine Exec Says It Expects Late-Stage Data for Bitopertin in Q4 This Year – Conf Call

THOMSON REUTERS
·
1 hour ago

Disc Medicine Exec Says the Policy Debate Over Accelerated Approval Has Stretched Across Multiple Administrations, and Recent Decisions Show Regulators Are Taking an "Increasingly Stringent" View of When Such Approvals Are Appropriate – Conf Call

THOMSON REUTERS
·
1 hour ago

Disc Medicine Addresses FDA Rejection of Bitopertin Filing

TIPRANKS
·
2 hours ago

Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
2 hours ago

Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path

TIPRANKS
·
3 hours ago

FDA Delays Disc Medicine's Rare Disease Drug

Benzinga_recent_news
·
4 hours ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)

TIPRANKS
·
Yesterday

Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval

Dow Jones
·
Feb 14

BUZZ-Disc Medicine dives as FDA declines to approve rare disease drug

Reuters
·
Feb 14

Disc Medicine down 32% to $49 after confirming rejection letter from FDA

TIPRANKS
·
Feb 14

Disc Medicine confirms complete response letter from FDA for bitopertin

TIPRANKS
·
Feb 14

Disc Medicine says issue raised by FDA ‘readily addressable’

TIPRANKS
·
Feb 14

US FDA declines to approve Disc Medicine's rare disease drug

Reuters
·
Feb 14

Disc Medicine Inc: Plans to Request a Type a Meeting to Review Our Approach With FDA

THOMSON REUTERS
·
Feb 14

Disc Medicine Inc - FDA Requires Results From Phase 3 Apollo Study for Decision

THOMSON REUTERS
·
Feb 14

Disc Medicine Inc: FDA Acknowledged That Aurora and Beacon Provided Sufficient Evidence That Bitopertin Significantly Lowers Ppix

THOMSON REUTERS
·
Feb 14

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

GlobeNewswire
·
Feb 14